1-5 of 5
Feng Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P209: Collaborative crosstalk between two apoptosis pathways drives synergy of dual inhibition of BCL-2/MDM2 in preclinical models of neuroblastoma

Free
Douglas D. Fang, Qiuqiong Tang, Qixin Wang, Yanhui Kong, Na Li, Feng Zhou, Ran Tao, Dajun Yang, Yifan Zhai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P209.
https://doi.org/10.1158/1535-7163.TARG-21-P209
Published: 01 December 2021
View article titled, Abstract P209: Collaborative crosstalk between two apoptosis pathways drives synergy of dual inhibition of BCL-2/MDM2 in preclinical models of neuroblastoma
Journal Articles

Abstract P208: Synergistic antitumor activity of lisaftoclax (APG-2575) and alrizomadlin (APG-115) through dual targeting of BCL-2/MDM2-P53 apoptotic pathways in preclinical models of acute myeloid leukemia

Free
Douglas D. Fang, Qiuqiong Tang, Qixin Wang, Na Li, Feng Zhou, Guoqin Zhai, Yan Yin, Dajun Yang, Yifan Zhai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P208.
https://doi.org/10.1158/1535-7163.TARG-21-P208
Published: 01 December 2021
View article titled, Abstract P208: Synergistic antitumor activity of lisaftoclax (APG-2575) and alrizomadlin (APG-115) through dual targeting of BCL-2/MDM2-P53 apoptotic pathways in preclinical models of acute myeloid leukemia
Journal Articles

Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma

Free
Chao Jiang, Rui Xu, Xiao-Xing Li, Yu-Feng Zhou, Xiao-Yi Xu, Yang Yang, Hui-Yun Wang, X.F. Steven Zheng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2610–2621.
https://doi.org/10.1158/1535-7163.MCT-17-0541
Published: 03 December 2018
View article titled, Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma
Open the PDF for Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma in another window
Journal Articles

Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma

Free
Feng Zhou, Michiko Shimoda, Laura Olney, Yuanzhi Lyu, Khiem Tran, Guochun Jiang, Kazushi Nakano, Ryan R. Davis, Clifford G. Tepper, Emanual Maverakis, Mel Campbell, Yuanpei Li, Satya Dandekar, Yoshihiro Izumiya
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (11): 2627–2638.
https://doi.org/10.1158/1535-7163.MCT-17-0041
Published: 01 November 2017
View article titled, Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma
Open the PDF for Oncolytic Reactivation of KSHV as a Therapeutic Approach for Primary Effusion Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract LB-C22: Acquired resistance to the cMET inhibitor savolitinib in lung cancer models through EGFR/mTOR/MYC deregulation and adoption of PIM signaling

Free
Ryan E. Henry, Evan R. Barry, Brendon Ladd, Aleksandra Markovets, Garry J. Beran, Yongxin Ren, Feng Zhou, Lillian Castriotta, Ammar Adam, Weiguo Qing, Weiguo Su, Edwin Clark, Celina M. D'Cruz, Alwin Schuller
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C22.
https://doi.org/10.1158/1535-7163.TARG-15-LB-C22
Published: 01 December 2015
View article titled, Abstract LB-C22: Acquired resistance to the cMET inhibitor savolitinib in lung cancer models through EGFR/mTOR/MYC deregulation and adoption of PIM signaling